Julie Kanter, MD

Julie Kanter, MD

Associate Professor, Division of Hematology & Oncology, The University of Alabama at Birmingham


Julie Kanter, MD
SCD Centers Workshop Co-Director
Associate Professor, Division of Hematology & Oncology
The University of Alabama at Birmingham
1720 2nd Avenue South, NP 2540
Birmingham, AL 35294-3300
Email: jkanter@uabmc.edu

Dr. Julie Kanter is a lifespan hematologist specializing in sickle cell disease. Dr. Kanter is the director of the adult sickle cell disease program and co-director of the comprehensive sickle cell research center at the University of Alabama at Birmingham. Dr. Kanter is very committed to improving outcomes in sickle cell disease and ensuring those outcomes reach the affected individuals. She works closely with national partners including the American Society of Hematology and the NIH on both advocacy and research. Dr. Kanter works on the development of novel therapeutics in sickle cell disease with expertise in clinical trial recruitment and trial design as well as in areas of improving access to care. Dr. Kanter and colleagues lead a large dissemination and implementation project to improve the use of TCD screening for stroke prevention in the United States. While in South Carolina, Dr. Kanter developed a statewide program (SC)2 forsickle cell disease, and she plans to develop a similar model of access to care in Alabama. Dr. Kanter has authored and co-authored more than 50 articles, book chapters, and abstracts and hopes to train upcoming physicians and providers in sickle cell disease to expand the workforce for treating affected individuals.

Dr. Julie Kanter has served as a Non-CE Consultant for Novartis, Guidepoint Global, GLG, Imara, Graphite, Axcella Health and Wells Fargo; served on Advisory Boards for BEAM, Forma, Agios, Novartis, Sanofi Novono. She has received honorarium from Novartis, Sanofi, Beam, Forma, NAMCP (National Association of Managed Care Providers); Research funding from NHLBI, HRSA, and CDC. She has served on a Steering Committee for Novartis and Astraeneca, and served as Membership on a Scientific Advisory Committee for Astrazeneca, Sanofi, Beam, Novartis, Acel Rx, Forma, NovoNordisc (DSMB), Sancillo (DSMB)


Highlights of previous years (2:15 PM - 2:45 PM)
Reflections on Day 1/ Welcome Year 2 Attendees (8:00 AM - 8:15 AM)
Highlights of Previous Years (2:15 PM - 2:45 PM)
Resource Fair (9:45 AM - 10:15 AM)
Reflections on Day 1/ Welcome Year 2 Attendees (8:00 AM - 8:15 AM)